Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...